FDA opens door to RMAT designations for therapies on clinical holdnews2026-03-18T18:54:41+00:00March 18th, 2026|Endpoints News|
FDA seeks to encourage fewer animal studies with new draft guidancenews2026-03-18T17:01:40+00:00March 18th, 2026|Endpoints News|
FDA approves J&J’s psoriasis pill Icotyde with $5B+ peak sales potentialnews2026-03-18T13:39:56+00:00March 18th, 2026|Endpoints News|
CMS innovation center to expand team focused on drug pricesnews2026-03-17T19:07:25+00:00March 17th, 2026|Endpoints News|
Aldeyra dry eye drug gets third rejection from FDA, triggering stock slidenews2026-03-17T18:30:14+00:00March 17th, 2026|Endpoints News|
Makary pushes for IRB reforms to catch China’s speedy trial startsnews2026-03-16T18:00:27+00:00March 16th, 2026|Endpoints News|
FDA merges adverse event trackers into one databasenews2026-03-11T19:44:22+00:00March 11th, 2026|Endpoints News|
FDA widens use of leucovorin without new trial datanews2026-03-10T13:00:12+00:00March 10th, 2026|Endpoints News|
Centauri Therapeutics granted FDA QIDP status for CTX-187 treatment of Gram-negative bacterial infectionsnews2026-03-10T12:23:05+00:00March 10th, 2026|Medical Device News Magazine|
Ipsen pulls cancer drug Tazverik from market over safety risksnews2026-03-09T18:16:40+00:00March 9th, 2026|Endpoints News|
